Skip to main content
. Author manuscript; available in PMC: 2018 Sep 11.
Published in final edited form as: Mod Pathol. 2017 Dec 1;31(2):214–234. doi: 10.1038/modpathol.2017.156

Figure 6.

Figure 6

In breast carcinomas, tumor-infiltrating lymphocytes are scored as the percentage of stromal space within the tumor area occupied by mononuclear immune cells. The degree and composition of tumor-infiltrating lymphocytes varies across tumor subtypes and primary organ sites. (a, b) Here a primary luminal A-type breast carcinoma (ER+/PR+/HER-2−/Ki67-low) contains minimal tumorinfiltrating lymphocytes (<5% of stromal area) (H&E, ×40 and ×400, original magnification). (c, d) In contrast, a primary HER-2+ breast carcinoma (ER−/PR−/HER-2+) contains brisk tumor-infiltrating lymphocytes (overall 80% of stromal area), qualifying as ‘lymphocyte predominant breast cancer’ (H&E, ×40 and ×400, original magnification).